Karyopharm Therapeutics Inc. [NASDAQ: KPTI] traded at a high on 01/04/23, posting a 3.68 gain after which it closed the day’ session at $3.38. The company report on January 4, 2023 that Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company’s senior management team will participate at the 41st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT, followed by a question-and-answer breakout session at 10:50 a.m. PT.
A live webcast of the presentation, along with accompanying slides, can be accessed under “Events & Presentations” in the Investor section of the Company’s website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event.
The results of the trading session contributed to over 3876629 shares changing hands. Over the past one week, the price volatility of Karyopharm Therapeutics Inc. stands at 11.18% while the volatility over the past one month is 10.49%.
The market cap for KPTI stock reached $254.11 million, with 80.21 million shares outstanding and 74.06 million shares in the current float. Compared to the average trading volume of 2.14M shares, KPTI reached a trading volume of 3876629 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Karyopharm Therapeutics Inc. [KPTI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPTI shares is $9.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPTI stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Karyopharm Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 04, 2022. The new note on the price target was released on February 09, 2022, representing the official price target for Karyopharm Therapeutics Inc. stock. Previously, the target price had yet another drop from $27 to $10, while Morgan Stanley kept a Equal-Weight rating on KPTI stock.
The Average True Range (ATR) for Karyopharm Therapeutics Inc. is set at 0.32, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 1.02.
How has KPTI stock performed recently?
Karyopharm Therapeutics Inc. [KPTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 36.29. With this latest performance, KPTI shares dropped by -34.37% in over the last four-week period, additionally sinking by -35.25% over the last 6 months – not to mention a drop of -52.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 44.30, with the RSI for the last a single of trading hit 50.34, and the three-weeks RSI is set at 42.42 for Karyopharm Therapeutics Inc. [KPTI]. The present Moving Average for the last 50 days of trading for this stock 4.41, while it was recorded at 3.17 for the last single week of trading, and 5.31 for the last 200 days.
Karyopharm Therapeutics Inc. [KPTI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Karyopharm Therapeutics Inc. [KPTI] shares currently have an operating margin of -43.33 and a Gross Margin at +98.00. Karyopharm Therapeutics Inc.’s Net Margin is presently recorded at -59.14.
Karyopharm Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.60.
Insider trade positions for Karyopharm Therapeutics Inc. [KPTI]
There are presently around $227 million, or 88.20% of KPTI stock, in the hands of institutional investors. The top three institutional holders of KPTI stocks are: STATE STREET CORP with ownership of 9,010,339, which is approximately -13.044% of the company’s market cap and around 1.40% of the total institutional ownership; BLACKROCK INC., holding 7,912,954 shares of the stock with an approximate value of $26.75 million in KPTI stocks shares; and PALO ALTO INVESTORS LP, currently with $19.0 million in KPTI stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Karyopharm Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 79 institutional holders increased their position in Karyopharm Therapeutics Inc. [NASDAQ:KPTI] by around 9,318,351 shares. Additionally, 68 investors decreased positions by around 10,029,075 shares, while 24 investors held positions by with 47,676,774 shares. The mentioned changes placed institutional holdings at 67,024,200 shares, according to the latest SEC report filing. KPTI stock had 19 new institutional investments in for a total of 3,548,200 shares, while 24 institutional investors sold positions of 2,898,117 shares during the same period.